Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

nab-paclitaxel

Celgene building

Celgene and Juno announce ten-year cancer deal

The firms’ pact will focus on the new area of immunotherapy

National Institute for Health and Care Excellence NICE logo

NICE no for new eye disease drug

Institute says ‘gaps and uncertainties’ in the treatment’s evidence directed its decision

National Institute for Health and Care Excellence NICE logo

NICE opens consultation on Gilead’s leukaemia drug

Comes after the Institute rejects the treatment in new draft guidance

- PMLiVE

Astellas’ Xtandi cancer drug rejected by NICE

England’s HTA questions the treatment’s efficacy and cost

- PMLiVE

Patient survey finds pharma falls short on drug pricing

The industry is coming under increasing attack from all sides as price tags rise

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

National Institute for Health and Care Excellence NICE logo

Roche, Novartis and Bayer gain NICE recommendations

Comes after the Institute effectively shut down for the General Election

- PMLiVE

New health ministers and re-appointments after reshuffle

Industry sees both continuity and change after the UK’s General Election

- PMLiVE

Celgene’s psoriasis pill gives ‘no added benefit’ to patients

Germany’s cost assessor IQWiG says Otezla is not value for money

- PMLiVE

Michael Zaiac moves from GSK to Celgene

He takes up the role of VP, medical affairs, haematology-oncology EMEA

- PMLiVE

Merck KGaA, Threshold gain FDA fast-track review

Industry partners hope their new cancer drug will be approved by the end of the year

- PMLiVE

George Freeman re-appointed as UK life science minister

Industry welcomes his continuation in this pharma-focused role

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links